Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ERAS-007

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Asana BioSci, Erasca, UT MD Anderson Cancer Center

Drug class:

ERK2 inhibitor, ERK1 inhibitor

Related drugs:

KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ERAS-007 Sensitive: C2 – Inclusion Criteria ERAS-007 Sensitive : C2	ERAS-007 Sensitive: C2 – Inclusion Criteria ERAS-007 Sensitive : C2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	ERAS-007 Sensitive: C2 – Inclusion Criteria ERAS-007 Sensitive : C2	ERAS-007 Sensitive: C2 – Inclusion Criteria ERAS-007 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ERAS-007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ERAS-007 + ERAS-601 Sensitive : C2	ERAS-007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ERAS-007 + ERAS-601 Sensitive : C2
NRAS G13D	Mantle Cell Lymphoma	NRAS G13D	Mantle Cell Lymphoma	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D
KRAS G13D	Pancreatic Adenocarcinoma	KRAS G13D	Pancreatic Adenocarcinoma	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D
NRAS Q61K	Neuroblastoma	NRAS Q61K	Neuroblastoma	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D
KRAS G13D	Colorectal Adenocarcinoma	KRAS G13D	Colorectal Adenocarcinoma	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D	ERAS-007 Sensitive: D – Preclinical ERAS-007 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	palbociclib + ERAS-007 Sensitive: D – Preclinical palbociclib + ERAS-007 Sensitive : D	palbociclib + ERAS-007 Sensitive: D – Preclinical palbociclib + ERAS-007 Sensitive : D
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + ERAS-007 Sensitive: D – Preclinical cetuximab + encorafenib + ERAS-007 Sensitive : D	cetuximab + encorafenib + ERAS-007 Sensitive: D – Preclinical cetuximab + encorafenib + ERAS-007 Sensitive : D
KRAS mutation	Pancreatic Ductal Adenocarcinoma	KRAS mutation	Pancreatic Ductal Adenocarcinoma	ERAS-007 + ERAS-601 Sensitive: D – Preclinical ERAS-007 + ERAS-601 Sensitive : D	ERAS-007 + ERAS-601 Sensitive: D – Preclinical ERAS-007 + ERAS-601 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ERAS-007 + ERAS-601 Sensitive: D – Preclinical ERAS-007 + ERAS-601 Sensitive : D	ERAS-007 + ERAS-601 Sensitive: D – Preclinical ERAS-007 + ERAS-601 Sensitive : D